Menopause – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Menopause Market Outlook

Thelansis’s “Menopause Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Menopause treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Menopause Overview

Menopause, a natural process in aging women, involves permanently ceasing menstrual periods for 12 months. A deficiency in estrogen causes this cessation and is not linked to any pathological condition. As women age, the number of ovarian follicles they possess decreases. The decline in granulosa cells, the primary producers of estradiol and inhibin, occurs in the ovary. This reduction leads to an absence of inhibition on gonadotropins, resulting in elevated production of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The increase in FSH levels tends to be more pronounced than LH due to LH's faster clearance from the bloodstream. The decrease in estrogen levels disrupts the hypothalamic-pituitary-ovarian axis, leading to a lack of endometrial development. Consequently, menstrual cycles become irregular before eventually ceasing altogether. It can be induced by surgical procedures like a hysterectomy with bilateral oophorectomy or by treatments for certain medical conditions such as endometriosis, breast cancer (using antiestrogens), and other cancers (due to chemotherapy medications). After menopause, the most prominent symptoms include genitourinary issues like vulvovaginal atrophy, dryness, and lower urinary tract problems such as urinary frequency, urgency, and nocturia. The core criteria for identifying menopause rely on the menstrual cycle, supported by laboratory tests. The female reproductive cycle is categorized into three phases: reproductive, menopause transition, and post-menopause. If left untreated, vasomotor symptoms usually fade after an average period of about 7.4 years.

• Premature natural menopause occurs before age 40, while early menopause occurs between 40 and 45. Roughly 10% of women experience menopause before age 45, 1.9% before 40, and 7.3% between 40 and 45. Considering the average life expectancy of 81 years for women in the US, up to 40% of their lives will be spent in the postmenopausal phase.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: